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ABSTRACT  
Carbon nanotubes (CNTs) are nanomaterials with interesting emerging applications. Their 25 
properties makes CNTs excellent candidates for use as new nanovehicles in drug delivery, 
immunization and diagnostics. In the current study, we assessed the immune-response-amplifying 
properties of CNTs to haptens by using azoxystrobin, the first developed strobilurin fungicide, as a 
model analyte. An azoxystrobin derivative bearing a carboxylated spacer arm (hapten AZc6) was 
covalently coupled to bovine serum albumin (BSA), and the resulting BSA–AZc6 conjugate was 30 
covalently linked to four functionalized CNTs of different shapes and sizes, varying in diameter and 
length. These four types of CNT-based constructs were obtained using efficient, fast, and easy 
functionalization procedures based on microwave–assisted chemistry. New Zealand rabbits and 
BALB/c mice were immunized with BSA–AZc6 alone and with the four CNT–BSA–AZc6 
constructs, both with and without Freund’s adjuvant. The IgG-type antibody responses were assessed 35 
in terms of the titer and affinity, paying special attention to the relationship between the immune 
response and the size and shape of the employed CNTs. Immunization with CNT–BSA–AZc6 
resulted in enhanced titers and excellent affinities for azoxystrobin. More important, remarkable IgG 
responses were obtained even in the absence of an adjuvant, thus proving the self-adjuvanting 
capability of CNTs. Immunogens were able to produce strong anti-azoxystrobin immune responses 40 
in rabbits even when administered at a BSA–AZc6 conjugate dose as low as 0.05 g. The short and 
thick CNT–BSA–AZc6 construct produced the best antibody response under all tested conditions.  
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1. Introduction 
Enhancement of the immune response against antigens is an area of great interest because of its 
impact on antibody production. One of the key steps in the immunization process is the phagocytosis 
of the antigen by professional antigen-presenting cells (APCs), such as macrophages, dendritic cells, 50 
and certain B cells.[1, 2] Once internalized by APCs, the antigen is processed into short peptide 
fragments. The presentation of these peptides by major histocompatibility complex (MHC) class II 
molecules can activate helper T cell responses that ultimately lead to the proliferation of plasma and 
memory B cells and to the production of high-affinity antibodies.[3-6]  
The efficiency of the phagocytosis process mainly depends on the size and surface properties of 55 
the antigen. Large and insoluble particulate antigens are phagocytosed very efficiently and produce 
strong responses by themselves.[7-9] This is the case for microorganisms such as bacteria and 
viruses.[10, 11] Conversely, small and soluble antigens, such as proteins and peptides, are poorly 
internalized and thus weakly immunogenic; therefore, an adjuvant is needed to intensify the immune 
response.[12, 13] Triggering an efficient immune response to low-molecular-weight compounds 60 
(haptens) is an even more challenging task because they are smaller and lack a peptide structure, so 
they cannot be presented by MHC II molecules unless they are conjugated to proteins prior to 
immunization.[14, 15] 
One of the emerging strategies for increasing the efficiency of the phagocytosis step, thereby 
enhancing the antibody response, is the use of nanomaterials that can increase the size of the antigen 65 
and modify its surface properties. Micro/nanoparticles (MPs/NPs) have been shown to be well-suited 
for increasing the immune response against protein and peptide antigens because the dimensions of 
particulate systems are comparable to those of microorganisms. Therefore, they can be better 
engulfed by APCs and the antigens can be delivered more efficiently.[16] There are basically two 
possible ways to take advantage of MPs/NPs for immunization purposes. One way consists of 70 
encapsulating the antigen inside liposomes[17, 18] or inside organic biodegradable polymers, such 
as poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA),[19-24] disulfide cross-linked 
polyacrylates,[25] or polysaccharides, such as pullulan[26] and chitosan.[27-29] This way, the 
particles can easily reach cytosol, where they are degraded, thus releasing the antigen. The other 
approach consists of attaching the antigen (covalently or not) to the functionalized surface of 75 
biocompatible and non-biodegradable particulate materials, such as lecithin NPs,[30] gold NPs,[31-
 3
33] quantum dots,[34] or MPs/NPs based on diverse organic polymers like polystyrene,[35, 36] 
polypropylene sulfide,[37] or polyacrylate.[38]  
Carbon nanotubes (CNTs) are nanomaterials of tubular shape with promising applications in 
biological and medicinal chemistry.[39-43] They are capable of crossing membranes to penetrate 80 
into different types of cells without causing cell death, so both the cell functionality and the activity 
of the introduced molecules are preserved.[44-46] Based on this finding, CNTs have been 
successfully employed as nanovehicles for drug delivery[43, 47, 48] and for the transport of 
biomolecules, such as proteins,[49] peptides,[50] and DNA[42, 51, 52], into cells. Additionally, 
based on their structural and chemical properties, CNTs can be envisioned as excellent carrier 85 
candidates in immunization protocols. They are very hydrophobic and insoluble because of their 
carbon skeleton structure, and they have a size on the micrometer/nanometer scale, mimicking the 
properties and size of bacteria. If an antigen is linked to a CNT, the resulting construct could be 
more easily phagocytosed and rapidly introduced into the immune system, thus improving the 
antibody response. Pantarotto et al.[53, 54] demonstrated the potential of using CNTs for animal 90 
immunization. In their seminal work, a peptide from the foot-and-mouth disease virus (FMDV) was 
covalently coupled to amino-derivatized single-walled carbon nanotubes (SWNTs), and this 
conjugate was administered to mice. Their results showed that this derivative, together with 
ovalbumin and an adjuvant, elicited high virus-neutralizing antibody responses in comparison with 
the non-conjugated peptide. Since this work, the advantages of immunization with proteins and 95 
peptides using CNTs have occasionally been confirmed,[55-58] but, to the best of our knowledge, no 
evidence of an enhancement in the immune response and antibody production against small 
molecules using CNTs as vehicles has been reported. The production of antibodies displaying high-
affinity and specificity to haptens is an important biotechnological research field because tailor-made 
binders can be used to develop immunoassays and biosensors for targets such as medicinal drugs, 100 
pesticides, drugs of abuse, environmental contaminants, food additives, hormones, toxins, etc.   
In the present work, we explore for the first time the potential of CNTs as self-adjuvating 
complexes in order to amplify the antibody response to haptens. Azoxystrobin, a molecule with three 
aromatic rings interconnected by ether linkages (Chart 1), was selected as the model hapten for this 
study. Azoxystrobin was the first discovered and patented antifungal of the strobilurin agrochemical 105 
family.[59] It is currently the world’s best-selling proprietary fungicide with global annual sales over 
$1 billion,[60] which makes the development of rapid immunochemical methods for this target a 
desirable goal. To evaluate the efficiency of CNTs as vehicles for immunization, rabbits and mice 
were injected with covalent CNT–BSA–hapten constructs. Special attention was paid to the 
relationship between the antibody response and the CNT size and shape. Animal immunization was 110 
carried out with functionalized single- and multi-walled nanotubes (SWNT and MWNT, 
respectively) that were either shortened or not by an acid oxidative treatment, so four types of CNTs 
differing in length and diameter were obtained and evaluated. The preparation of this group of 
functionalized CNTs was performed using fast and easy procedures based on optimized microwave-
assisted chemical methods. Finally, the ability of CNTs to efficiently trigger an immune response by 115 
themselves, without the need for conventional adjuvants, was also investigated. 
 
 
 
 120 
Chart 1. Structure of azoxystrobin and of the AZc6 hapten. 
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2. Materials and methods 125 
2.1. Chemicals and instrumentation  
Pristine SWNTs (90 wt%, 1-2 nm in diameter, 5-30 m in length) and MWNTs (95 wt%, 50-80 
nm in diameter, 10-20 m in length) were purchased from Cheap Tubes Inc. (Brattleboro, VT, USA) 
and used as received. Solvents and reagents for CNT functionalization and for immunogen 
preparation were obtained from Sigma-Aldrich (St. Louis, MO, USA) and used without further 130 
purification. Succinic acid peroxide was obtained from the H2O2 treatment of succinic acid 
anhydride, as previously described.[61] The synthesis of hapten AZc6, as well as the preparation and 
purification of the immunizing BSA–AZc6 conjugate (5) and the coating conjugate OVA–AZc6 for 
the indirect competitive ELISA, has been previously described.[62]  
Microwave reactions were performed in a CEM Discover S-Class reactor (Matthews, NC, USA) 135 
equipped with an infrared pyrometer for temperature control, a pressure control system, magnetic 
stirring, and a simultaneous air-cooling option. Open vessel reactions were conducted using 
conventional glassware, whereas pressurized reactions were performed in CEM supplied microwave 
quartz special vessels. Nylon membranes with a pore size of 0.45 m were purchased from GE 
Power & Water (Trevose, PA, USA) for vacuum filtration of CNT samples. The reaction progress 140 
was observed by measuring the zeta potential of the samples in deionized water using a  Malvern 
Zetasizer Nano ZS apparatus (Worcestershire, UK). TEM images were obtained using a JEOL 100 
kV JEM-1010 microscope (Tokyo, Japan) equipped with a MegaView III digital camera and with 
the Analysis image acquisition software.  
Azoxystrobin was kindly provided by Syngenta (Basel, Switzerland). Concentrated stock solutions 145 
were prepared in anhydrous DMF and stored at −20 ºC. Polyclonal goat anti-rabbit IgG–peroxidase 
antibody (GAR–HRP) was obtained from BioRad (Madrid, Spain). Polyclonal rabbit anti-mouse 
IgG–peroxidase antibody (RAM–HRP) was obtained from Dako (Glostrup, Denmark). Polyclonal 
goat anti–mouse IgG–gold antibody (5 nm colloidal gold), o-phenylenediamine, complete and 
incomplete Freund’s adjuvants, Tween 20 and other reagents for immunoassays were purchased 150 
from Sigma-Aldrich (Madrid, Spain). The preparation of the mouse IgG anti-AZc6 mAb was 
previously described.[63] Costar 96-well, flat-bottom, high-binding, polystyrene ELISA plates were 
obtained from Corning (Corning, NY, USA). The microplates were washed using an ELx405 
microplate washer from BioTek Instruments (Winooski, VT, USA), and the ELISA absorbances 
were read using a PowerWave HT reader, also from BioTek Instruments.  155 
 
2.2. Oxidative fragmentation procedure. 
100 mg of SWNTs or MWNTs were suspended in 25 mL of a 70% HNO3 solution in a microwave 
quartz vessel and sonicated for 15 min. The vessel was closed, and the mixture was irradiated for 30 
min at 190 ºC and at 250 W under a pressure of 19 bar with magnetic stirring and simultaneous air-160 
cooling. Next, the cooled reaction mixture was diluted in 250 mL of deionized water and filtered 
through a 0.45 m nylon membrane. The resulting black solid was collected, resuspended in 100 mL 
of water, sonicated, filtered again, and washed with water. Finally, the air-dried solids were 
suspended in deionized water at a concentration of 1 mg/mL and sonicated for 5 min to obtain stable 
solutions of 1a and 2a with zeta potential values of −35 and −50 mV, which were stored at 4 ºC. 165 
 
2.3. Succinic acid peroxide radical insertion procedure. 
100 mg of SWNTs or 50 mg of MWNTs were suspended in 30 mL of o-dichlorobenzene in a 
conventional round-bottom flask, and 5 g of succinic acid peroxide were added. The mixture was 
sonicated for 15 min in an ultrasonic bath and then irradiated for 30 min at 115 ºC and at 250 W 170 
under magnetic stirring and simultaneous air-cooling, keeping the vessel open to allow release of the 
CO2 formed. After 15 min of elapsed time, additional succinic acid peroxide (5 g) was added using a 
solid addition funnel. After cooling, the reaction mixture was diluted with 50 mL of THF, sonicated 
for 15 min and then filtered through a 0.45 m nylon membrane. The black solid was collected, 
suspended in 50 mL of acetone, sonicated, filtered again, and washed with acetone. Finally, the air-175 
dried solids were suspended in deionized water (at a concentration of 1 mg/mL) and sonicated for 5 
min to obtain stable suspensions of 3a and 4a with zeta potential values of −40 and −32 mV, which 
were stored at 4 ºC. 
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2.4. Synthesis of CNT–NH2 derivatives 1b and 3b. 
80 mg of CNTs 1a or 3a were suspended in a mixture of ethylendiamine and N-methylpyrrolidone 180 
(3 mL each) in a microwave quartz vessel and sonicated for 15 min. The reaction vessel was closed, 
and the mixture was irradiated for 30 min at 190 ºC and at 250 W under a pressure of 6 bar with 
magnetic stirring and simultaneous air-cooling. The cooled reaction mixture was diluted in 20 mL of 
THF and processed as in the previous procedure. Finally, the black solids obtained were suspended 
in deionized water at a concentration of 1 mg/mL and briefly sonicated to give stable suspensions of 185 
1b and 3b with zeta potential values of +35 mV, which were stored at 4 ºC. 
 
2.5. Synthesis of CNT–NH2 derivatives 2b and 4b. 
50 mg of CNTs 2a or 4a were suspended in a mixture of 3 mL of DMSO and 2 mL of 
N-methylpyrrolidone in a microwave quartz vessel and sonicated for 15 min. The reaction vessel 190 
was closed, and the mixture was irradiated for 30 min at 180 ºC and at 280 W under a pressure of 6 
bar with magnetic stirring and simultaneous air-cooling. The cooled reaction mixture was diluted in 
20 mL of THF and processed as previously described to obtain 1 mg/mL aqueous stable dispersions 
of 2b and 4b with zeta potential values of +30 mV, which were stored at 4 ºC.   
 195 
2.6. Synthesis of CNT–BSA–AZc6 immunizing conjugates 
20 mL of a 0.1 mg/mL solution of conjugate 5 in 100 mM phosphate buffer, pH 7.4, were mixed 
with 20 mL of a 1 mg/mL solution of each CNT–NH2 (1b, 2b, 3b, or 4b) in deionized water. 180 mg 
of EDC were added, and the resulting mixture was stirred at room temperature for 2 h. Next, the 
crude mixture was filtered through a 0.45 m nylon membrane and washed with water. The black 200 
solid was collected, suspended in water, sonicated, filtered again, and washed. This process was 
repeated three times. Finally, the solids were suspended in water at a concentration of 1 mg/mL by 
using brief sonication to give stable solutions of the corresponding CNT–BSA–AZc6 derivatives 
(1c, 2c, 3c, and 4c), which showed zeta potential values between −11 and −15 mV. These solutions 
were stable for a long time when stored at 4 ºC. 205 
 
2.7. Synthesis of CNT–AZc6 (3d). 
100 L of a 1 mM solution of hapten AZc6 in DMF, 200 mg of EDC, and 20 mg of sulfo–NHS 
were consecutively added to 20 mL of a 1 mg/mL aqueous solution of 3b in 100 mM phosphate 
buffer, pH 7.4, and the resulting mixture was stirred for 2 h at room temperature. The CNT 210 
derivative formed (3d) showed a zeta potential close to 0 mV and became insoluble in water, so they 
easily aggregate and precipitate. The crude mixture was filtered through a 0.45 m nylon membrane 
and washed, first with water and then with acetone (suspending, sonicating and filtering the solid 
with each solvent washing). The precipitated conjugate 3d was stored in water at 4 ºC. 
 215 
2.8. Characterization by immuno–TEM 
CNT–BSA–AZc6 aqueous solutions were deposited onto grids (a Formvar support film on a 
copper 400 mesh-grid). After evaporation of the solvent, samples were incubated for 2 h with a 1 
g/mL solution of the specific mouse IgG anti-AZc6 mAb in 1% goat serum, washed three times 
with Tris-buffered saline, and incubated for 2 h with goat anti–mouse IgG–gold antibody (1/500) in 220 
a Tris buffer containing 1% BSA + 0.5% Tween 20. Finally, after several washings with PBS and 
evaporation of the solvent, the samples were visualized using the TEM microscope. 
 
2.9. Determination of the amount of conjugate 5 attached to the CNTs 
CNT-based immunogens were diluted in PBS and analyzed in triplicate following the ELISA 225 
procedure described below. For this purpose, solutions of CNT constructs were added to the plate in 
the competitive step with the anti-AZc6 mAb. In the case of CNT–BSA–AZc6 immunogens, 
standard curves of conjugate 5 in PBS were employed to interpolate the ELISA signals, whereas for 
the quantification of the hapten AZc6 in 3d standard curves were prepared using the hapten itself.  
 230 
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2.10. Animal immunization and antibody production 
Animal manipulation was performed in compliance with Spanish laws and guidelines (RD 
1201/2005 and law 32/2007) and according to the European Directive 2010/63/EU concerning the 235 
protection of animals used for scientific purposes. Female BALB/c mice and New Zealand rabbits 
were supplied by Charles River Laboratories (L’Arbresle, France). Rabbits were immunized 
subcutaneously at three-week intervals with the appropriate amount of CNT derivatives. When 
adjuvant was used, the CNTs aqueous solution was emulsified with the same volume of complete 
FA for the first injection and of incomplete FA for additional doses. For each injection, a total 240 
volume of 1 mL was evenly distributed among several sites along the back. When the immunization 
was performed without FA, 1 mL of the CNT derivative in aqueous suspension was administered at 
each injection. Ten days after each dose, a blood sample was taken from the ear vein, and, ten days 
after the fourth dose, the animals were exsanguinated by cardiac puncture. Antisera were obtained by 
centrifugation, diluted 1/5 with PBS containing 0.01% thimerosal, and stored at 4 ºC in amber vials 245 
for daily use. For long term storage, the antisera were precipitated twice with ammonium sulfate.   
Eight groups of three BALB/c female mice (8−10 weeks old) were immunized at three-week 
intervals by intraperitoneal injections, each group with one of the described CNT–BSA–AZc6 
constructs at the appropriate concentration, with or without FA. Immunogens, essentially prepared as 
reported above for rabbits, were administered in a total volume of 200 L per injection. An 250 
additional group of mice were immunized with protein conjugate 5 (2 µg) emulsified with FA as a 
control. Antisera were obtained by tail bleeding 10 days after the fourth dose, diluted 1/5 with PBS 
containing 0.01% thimerosal, and stored at 4 ºC in amber vials. 
 
2.11. ELISAs 255 
96-well polystyrene ELISA plates were coated with 100 μL per well of the OVA–AZc6 conjugate 
solution (0.1 µg/mL) in 50 mM carbonate−bicarbonate buffer, pH 9.6, by overnight incubation at 
room temperature. The coated plates were washed four times with washing solution (150 mM NaCl 
containing 0.05% Tween 20), and they received 50 μL per well of the azoxystrobin solution plus 50 
μL per well of the mouse or rabbit antisera. From a concentrated azoxystrobin stock solution in 260 
DMF, calibration curves were prepared in borosilicate glass tubes by serial dilution in PBS. A blank 
was included in each curve. The competitive immunological reaction took place within 1 h at room 
temperature, and the plates were washed again as described. Next, 100 μL per well of the appropriate 
secondary HRP-labeled antibody solution in PBST (PBS containing 0.05% Tween 20) were added, 
and the plates were incubated for 1 h at room temperature. In the case of experiments with rabbit 265 
antisera, a 1/10000 dilution of GAR−HRP was used, whereas with mouse antisera a 1/2000 dilution 
of the RAM−HRP conjugate was employed. After the plates had been washed as described, the 
colorimetric signal was generated by the addition of 100 μL per well of a freshly prepared substrate 
solution (2 mg/mL OPD and 0.012% (v/v) H2O2 in 25 mM citrate and 62 mM phosphate buffer, pH 
5.4). The enzymatic reaction was stopped after 10 min at room temperature by adding 100 μL per 270 
well of 2.5 M sulfuric acid. The absorbance was immediately read at 492 nm, using 650 nm as a 
reference wavelength. Competitive curves were obtained by plotting mean absorbance values vs. the 
logarithm of analyte concentration. The resulting sigmoidal curves were fitted to a four-parameter 
logistic equation using the SigmaPlot software package from SPSS Inc. (Chicago, IL). The 
antiserum apparent affinity was estimated as the concentration of azoxystrobin at the inflection point 275 
of the fitted inhibition curve, also referred to as IC50. Titer refers to the antiserum dilution that 
produces a maximum absorbance equal to 1.0 under the above described assay conditions. 
 
 
  280 
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3. Results and discussion 
3.1. Synthesis of the CNT-based immunogens 
To assess the relationship between the CNT size and shape and the triggered immune response, 
four types of CNT–BSA–hapten immunogens, differing in length and diameter, were prepared 
(Scheme 1): short and thin (1c), short and thick (2c), long and thin (3c), and long and thick (4c). 285 
Previous studies on the influence of particle size on the cellular uptake and immune response were 
carried out with nanoparticulate materials, such as PLGA,[64, 65] gold,[31] and polystyrene.[9, 66] 
Concerning haptens, valuable antibodies have been recently reported using aluminium oxide 
nanoparticles, nanoparticulated adjuvants, and amphiphilic poly (γ-glutamic acid)[67, 68]. However, 
similar studies with CNTs and haptens have not been undertaken. 290 
 
 
 
Scheme 1. Synthesis of the CNT–BSA–AZc6 constructs 1c, 2c, 3c, and 4c. 
 295 
 
Because of the stability and low reactivity of pristine CNTs, their conventional functionalization 
often requires harsh conditions and reaction times that can take several days. It is well known that 
CNTs absorb microwave energy because of their structure,[69, 70] allowing them to react more 
easily when using microwaves than when using conventional heating. In fact, microwave-assisted 300 
chemistry has become a very attractive and useful tool for the fast and effective functionalization of 
CNTs in recent years.[71, 72] Accordingly, synthesis of the four types of CNTs employed in this 
work was accomplished using pristine SWNTs and MWNTs and rapid, straightforward procedures 
based on microwave-assisted chemistry. Commercial CNTs are long tubes (5-30 m), and while 
SWNTs are very thin (1-2 nm), MWNTs are comparatively thick (50-80 nm). We adapted and 305 
optimized two general microwave methods in order to functionalize both types of CNTs with 
adequate moieties for hapten and conjugate coupling, i.e., acid oxidative fragmentation and succinic 
acid peroxide radical insertion (Scheme 1). The first procedure cuts the CNTs into fragments, 
inducing the opening of tube caps and the formation of holes in sidewalls. The resulting acid-cut 
CNT fragments are often less than 1 m in length and include carboxylate moieties at the ends and 310 
on the sidewalls of the tubes. On the other hand, radical insertion methods allow the introduction of 
carboxy–alkyl moieties via a carboxy–alkyl radical attack on the aromatic network of the sidewalls. 
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This way, functional groups are introduced only on the sidewalls, and the length of the CNTs 
remains essentially unmodified.  
In the oxidative fragmentation method, SWNTs and MWNTs were treated with concentrated 315 
HNO3 at a high temperature and pressure under microwave irradiation[73] for 30 min. The progress 
of the carboxylation reaction was observed by measuring changes in the zeta potential values. After 
the reaction, acid-cut CNTs, 1a and 2a, showed excellent solubility in water (up to 1 mg/mL) and 
zeta potential values of −35 and −50 mV, confirming the existence of numerous negatively charged 
carboxylate groups on the CNT surface.  320 
Incorporation of carboxylate functional groups with minor modification of the nanotube length 
was achieved by using a new microwave-assisted radical insertion method. Previous procedures for 
introducing alkyl groups into CNTs using radical insertion with acyl peroxides[61, 74-76] often 
involved long reaction times and/or large amounts of peroxide were consumed. We describe a new 
radical insertion method for alkyl chains performed under microwave conditions. Based on previous 325 
work by Peng et al.,[61] we adapted the conventional heating conditions to efficiently incorporate a 
carboxyethyl moiety on the sidewalls of SWNTs and MWNTs through a C–C bond. The treatment 
of pristine CNTs with succinic acid peroxide in o-dichlorobenzene at 115 ºC under microwave 
irradiation shortened the reaction time from 10 days to approximately 30 min. Carboxyethyl 
functionalized CNTs, 3a and 4a, showed a water solubility equivalent to the acid-cut nanotubes and 330 
negative zeta potential values of −40 and −32 mV, which indicate adequate functionalization of the 
CNT sidewall surface. 
The next step in the preparation of CNT-based immunogens was the introduction of an 
ethylendiamine moiety through a covalent amide bond between the available carboxylate groups on 
the CNT surface and one of the amine groups in ethylendiamine. The synthesis of these types of 335 
derivatives in two steps, using conventional methods, has been previously described.[61, 77] 
Recently, microwave-assisted protocols have been used in order to achieve this amide bond in CNTs 
in only one step and without activating reagents.[78-80] Based on the procedure described by 
Bezdushna et al.[81] for the amidation of poly(ether sulfone) carboxylated polymers and starting 
from 1a and 3a, we prepared the amidated SWNTs 1b and 3b in a single 30 min step solely using 340 
ethylendiamine and N-methylpyrrolidone (Scheme 1). Both types of amidated SWNTs showed zeta 
potential values of +35 mV. The change in the sign of the zeta potential was indicative of the 
negatively charged carboxylate residues on the surfaces of the CNTs being substituted by positively 
charged amine moieties. Like their carboxylated counterparts (CNT–COOH), these amino-aminated 
particles (CNT–NH2) showed good water solubility, close to 1 mg/mL. 345 
To achieve a direct one-step formation of the amide bond in the carboxylated MWNTs 2a and 4a, 
which showed a much lower reactivity, a better microwave-absorbing solvent (DMSO instead of 
N-methylpyrrolidone) was required. With this solvent change, it was possible to obtain the desired 
amido-amidated MWNTs 2b and 4b with adequate water solubility and zeta potential values (+30 
mV in both cases). 350 
Finally, all four types of CNT–NH2 (1b, 2b, 3b, and 4b) were covalently coupled to the protein–
hapten conjugate BSA–AZc6 (5) via an amide bond between the amine moieties on the surfaces of 
the CNTs and the available carboxylate groups from the aspartate and glutamate residues in the 
BSA–hapten conjugate (Scheme 1). Conjugate 5 was prepared[62] with a high hapten–to–protein 
molar ratio (MR=26), thus blocking most of the available amine residues in the protein and 355 
minimizing protein cross-linking. Conjugate coupling was achieved using standard bioconjugation 
techniques, i.e., aqueous dispersions of each CNT–NH2 derivative were mixed with a solution of 5 in 
phosphate buffer, pH 7.4, in the presence of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
(EDC) as a coupling agent. CNT–BSA–AZc6 constructs (1c, 2c, 3c, and 4c) showed zeta potential 
values between −11 and −15 mV and good solubility in water. Although these properties 360 
qualitatively indicated that the coupling reaction had occurred, the amount of 5 attached to the 
nanotubes was quantified by using an ELISA to confirm this point, employing an anti-AZc6 
monoclonal antibody (mAb) previously produced in our lab.[63] Loading values for 5 of 
approximately 18, 10, 10, and 7 g per milligram of CNT were calculated for 1c, 2c, 3c, and 4c, 
respectively. Instead of using other common procedures for protein quantification, such as TGA,[72, 365 
76] the Kaiser test for amine residues,[53, 77] or Bradford analysis of the unbound protein,[55] the 
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ELISA technique was chosen to estimate the protein loading in CNTs because this method gives the 
amount of conjugate through the interaction with the antibody, thus confirming that the hapten is 
actually exposed to the environment and therefore free to interact with antibodies and cell receptors 
during the immune response.  370 
An additional CNT immunogen was prepared which comprised just the hapten AZc6 directly 
attached to a CNT (3d, CNT–AZc6). This construct was used as a negative control based on the 
widely accepted requirement of a polypeptide in order to produce antibodies against haptens. The 
hapten AZc6 was conjugated to the amino-aminated SWNT 3b using EDC and sulfo-NHS as 
coupling reagents. The immunogen 3d (Scheme 2) showed a zeta potential value close to 0 mV and 375 
very poor water solubility, although it was soluble in DMF at 1 mg/mL. The concentration of AZc6 
linked to CNTs, quantified by an ELISA with the anti–AZc6 mAb, was 0.26 g of hapten per 
milligram of CNT. 
 
 380 
Scheme 2. Synthesis of the CNT–AZc6 conjugate (3d). 
 
3.2. TEM characterization of CNT-based immunogens 
Immuno–TEM was carried out to simultaneously characterize the CNT derivatives in terms of 
size and shape and to image the distribution of the conjugate BSA–AZc6 (5) over the CNT walls. 385 
Briefly, CNT–BSA–AZc6 particles were labeled with the anti–AZc6 mAb and then incubated with a 
gold-labeled goat anti-mouse IgG antibody. Fig. 1 shows the immuno-TEM images of the four types 
of CNT–BSA–AZc6 immunogens. The sharp black dots observed in these photographs confirmed 
the presence of single molecules of 5 covalently immobilized on the surface of all four types of 
functionalized CNTs. The TEM images of 1c and 2c showed that shortened CNTs that did not 390 
exceed 1 m in length (they were typically between 400 and 600 nm in length; Fig. 1A and 1B), 
which proved the effectiveness of the acid–oxidation procedure for cutting CNTs into shorter 
segments. Derivatives 1c were visualized as individual thin needles 2 nm in diameter (Fig. 1A), 
whereas 2c were imaged as individual thick tubular structures approximately 50 nm in diameter (Fig. 
1B). For 3c and 4c, the TEM images showed longer CNTs several micrometers in length (Fig. 1C 395 
and 1D), thus showing that the radical insertion strategy better preserved the original length of the 
pristine CNTs. In the case of 3c, the diameter of each individual CNT was approximately 2 nm, but 
they showed a tendency to group together, forming bundles that can reach up to 100 nm in diameter 
(Fig. 1C), whereas each individual 4c showed a diameter of approximately 50 nm (Fig. 1D). 
Interestingly, an internal small-diameter cylindrical channel can be clearly observed in both 4c and 400 
2c derivatives. 
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Fig. 1. Immuno–TEM images of CNT–BSA–AZc6 constructs 1c (A), 2c (B), 3c (C), and 4c (D). 
 405 
3.3. Rabbit antibody response with CNT-based immunogens 
Aqueous solutions of the four CNT–BSA–AZc6 immunogens (1c, 2c, 3c, and 4c; Table 1) were 
subcutaneously administered to rabbits with and without Freund’s adjuvant (FA), which is probably 
the most common adjuvant for antibody production in experimental animals. The volumes were 
adjusted in order to inoculate the animals with 5 g of conjugate 5. CNT–AZc6 (3d) emulsified with 410 
FA was also injected into control animals. Three additional controls were also employed: 5 and 50 
g of 5 emulsified with adjuvant, and a mixture of 300 g of 5 with 1 mg/mL of 3b in phosphate-
buffered saline (PBS). It is worthwhile noting that 5 g is a much lower amount of protein than the 
most frequently used dose in standard protocols for rabbit immunization (usually 0.1–1 mg).[82]   
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Table 1. Main structural features of the CNT–BSA–AZc6 constructs (1c, 2c, 3c, and 4c) and the 
CNT–AZc6 construct (3d). 
 1c 2c 3c 4c 3d 
 
  
 
 
 
 
Conjugate loading  (g 5/mg CNT) 18 10 10 7  
Hapten loading  (g AZc6/mg CNT) 3.03 1.68 1.68 1.18 0.26 
Zeta potential (mV) −15 −13 −13 −11  0 
Functionalization procedurea ox ox rad rad rad 
Solubility in water (1 mg/mL)b + + + + − 
 
Average dimensions:      
Diameter (nm) 2 50 2c 50 2 
Length (m) 0.5 0.5 > 2 > 2 >2 
a Oxidative fragmentation (ox) or succinic acid peroxide radical insertion (rad).  
b Solubility in water at 1 mg/mL. Soluble (+) or not soluble (–). 
c The diameter of each individual 3c construct is 2 nm, but in the TEM micrographs these tubes tend to aggregate forming 
bundles that could reach up to 100 nm thick.  
 
 
 415 
The animals received a total of four doses of immunogen. Ten days after each injection they were 
bled, and the presence of anti-azoxystrobin antibodies in the serum samples was evaluated by 
ELISA. Fig. 2 shows the evolution of the immune response to azoxystrobin for each immunogen in 
terms of the antiserum titer (Fig. 2A) and antibody affinity (IC50; Fig. 2B). All four types of 
CNT-based immunogens were capable of producing IgG responses having outstanding titers and 420 
affinities to azoxystrobin. Remarkably, 5 g of conjugate was unable to trigger a significant 
response when administered alone, i.e., not attached to CNTs (legend “5 (1×) + FA” in Fig. 2A). In 
fact, it was necessary to use an amount of conjugate 10–fold larger (50 g) in order to achieve a 
nearly equivalent output (legend “5 (10×) + FA” in Fig. 2A). In our opinion, these results showed 
the practical capability of CNTs for enhancing the immune response against haptens by acting as 425 
efficient delivery vehicles. More important, CNTs worked very effectively as immunizing carriers 
even in the complete absence of FA, as injections with aqueous solutions of CNT–BSA–AZc6 
constructs demonstrated. Although slightly lower titers were obtained (Fig. 2A), anti-azoxystrobin 
antibodies produced from CNT immunogens without FA showed affinities comparable to or even 
better than those obtained with the positive control (Fig. 2B). Moreover, the fact that the titers 430 
gradually increased with booster doses, whereas the IC50 values decreased down to 1 nM, is 
indicative of a regular affinity maturation process. 
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Fig. 2. Evolution of the anti-azoxystrobin IgG response in rabbits immunized with 5 µg of protein conjugate 5 
attached to the different CNT derivatives (1c, 2c, 3c, and 4c) with and without FA; 50 µg (10x) and 5 µg (1x) 
of 5 + FA (standard procedure); 300 µg (60x) of 5 + 3b (non-covalent mixture of protein conjugate and 440 
CNT); and 3d (0.13 µg of hapten AZc6 without carrier protein + FA). A) Evolution of the antibody titer. B) 
Evolution of the antibody affinity estimated from the IC50 values obtained from competitive inhibition curves 
with azoxystrobin standards. Values are the mean of two independent experiments. 
 
To the best of our knowledge, this is the first reported evidence supporting the self-adjuvanting 445 
capacity of CNTs for the production of high–affinity antibodies. CNT immunogens are comparable 
in shape and size to bacteria, so they can be very easily phagocytosed by APCs, which most likely 
makes the immunostimulatory effect of classical adjuvants unnecessary. This finding has interesting 
applications for the routine production of antibodies with biotechnological and diagnostic purposes, 
because immunizations without classical adjuvants are much easier, cheaper, faster, and less painful 450 
for animals. The contraindications and negative health effects of the adjuvants employed in animal 
experimentation, including FA, have been widely described,[67, 83] and the painful consequences 
for the skin are also well known. In our experiments, rabbits showed no skin damage, no wounds, 
and no apparent negative reactions when subcutaneously injected with CNT constructs in buffer. In 
line with our results, excellent examples of the production of anti-hapten antibodies using different 455 
nanoparticles as safe delivery vehicles have been recently reported for several low molecular weight 
chemicals.[67, 68] 
No IgG response against azoxystrobin was observed in rabbits immunized with 3d + FA (without 
carrier protein) or with the 5 + 3b mixture (no covalent linking with the CNT). The absence of a 
response with 3d confirms the paradigm that a protein is required for the effective production of 460 
anti-hapten antibodies. Although nanoparticles increase the size of the immunogen and allow a better 
uptake by macrophages, only peptide fragments generated after antigen processing can be linked to 
MHC II molecules on the APCs surfaces.[14] Nevertheless, Maquieira et al. [68] have recently 
reported the existence of a secondary immune response with haptens covalently linked to aluminum 
oxide nanoparticles, even though further research is probably required to fully clarify the underlying 465 
mechanism. On the other hand, the lack of response with the 5 + 3b mixture shows that non-covalent 
interactions between the positively charged CNT 3b and the negatively charged protein conjugate 5 
are not sufficient to preserve the integrity of the immunogen; so, a covalent bond between the CNT 
and the protein–hapten conjugate is needed for proper antigen delivery inside cells. 
Finally, Fig. 2 reveals significant differences in the antibody response as a function of CNT size 470 
and shape. Our results indicate that CNT vehicles with similar diameters work better if they have 
shorter lengths. Thus, construct 2c elicited higher titers and better affinities than 4c, and 1c also 
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evoked higher titers than 3c, though similar affinities. Construct 4c turned out to be the worst 
immunogen, whereas 2c clearly displayed the best performance, exhibiting the highest titer and the 
best affinity after the last immunization (IC50=1 nM), both with and without FA. 475 
To gain further insight into the amplifying effect observed for CNT-based constructs, the four 
immunogens were additionally assessed by immunizing animals with a 10-fold lower amount of 
protein conjugate 5 (0.5 µg per rabbit). Additionally, immunogen 2c was also evaluated at an even 
lower dose (0.05 µg of conjugate 5). As shown in Table 2, significant IgG responses were still 
observed for all four CNT-based immunogens at these low doses (with titers ranging from 1/100 to 480 
1/5000, depending on the type of CNT), whereas no response was observed as before when 5 ug of 
conjugate 5 was administered by conventional protocols, i.e., without being covalently bound to 
CNTs. Furthermore, titers close to 1/1000 and IC50 values lower than 10 nM were still obtained in 
rabbits immunized with 0.05 µg of 2c, still the best-performing CNT construct. These results 
confirm that CNTs could be useful as delivery systems for obtaining strong antibody responses even 485 
with antigen amounts 1000-fold lower than typical doses used for rabbit polyclonal antibody 
production. 
 
 
Table 2. Main immunological features of the CNT–BSA–AZc6 constructs (1c, 2c, 
3c, and 4c) a 
  1c 2c 3c 4c 
  
  
 
 Amount of protein 
conjugate 5  
5 g  Titer (log) 3.1 3.7 3.4 2.1 
IC50 (nM) 3.8 1.0 3.1 12.0 
5 g + FA Titer (log) 4.9 4.6 3.3 4.1 
IC50 (nM) 3.4 1.0 3.9 16.0 
0.5 g + FA Titer (log) 2.9 3.7 2.3 2.1 
IC50 (nM) 9.0 9.6 70.0 20 
0.05 g + FA Titer (log) n.t.
b 3.0 n.t. n.t. 
IC50 (nM) n.t. 7.8 n.t. n.t. 
a Rabbit immune response against azoxystrobin after the fourth boost (n=2). Results for 3d are not 
shown due to the complete lack of response, even when using FA.  
b Not tested. 
 
 490 
 
Remarkably, azoxystrobin competitive inhibition curves with rabbit antisera obtained from 
immunogen 2c at different doses perfectly fitted a four-parameter logistic equation, displaying 
analytical features equivalent to those of the curve with a rabbit antiserum that was obtained under 
standard immunization conditions (Fig. 3). 495 
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Fig. 3. Representative azoxystrobin inhibition curves with rabbit antisera obtained from 2c. The azoxystrobin 
standard curve with rabbit antiserum obtained using a standard immunization protocol with 50 µg of 5 in FA 500 
(○) was included as a control. Dashed lines show the azoxystrobin standard curves with rabbit antisera 
obtained from different amounts of 2c: () 5 µg + FA, () 0.5 µg + FA, () 0.05 µg + FA, and () 5 µg 
without FA (expressed as total content of protein conjugate 5). Equivalent results were obtained in a 
replicated independent experiment.  
 505 
 
 
3.4. Mouse antibody response with CNT-based immunogens 
Additional immunization experiments were carried out on mice – a widely used animal model for 
experimental research and particularly for the production of monoclonal antibodies. Groups of 3 510 
mice were immunized intraperitoneally with 2 g of protein conjugate 5 attached to each CNT 
derivative, either in aqueous solution or emulsified with FA. As a control, an additional group of 3 
mice was immunized with 2 g of 5 in FA without CNT. Each animal received a total of four 
injections. Ten days after the fourth dose, blood samples were taken, and the antisera were assessed 
by ELISA. All of the CNT–based immunogens elicited a strong IgG response, displaying titers even 515 
higher than the control, particularly for the shortest particles. This result confirmed 1c and 2c as the 
best constructs for antibody production also in mice and through a different inoculation route (Fig. 
4). Moreover, antisera from immunogens 1c and 2c also showed superior affinity to the target, with 
azoxystrobin IC50 values lower than 50 nM. The most important result emerging from this 
immunization experiment is the unequivocal capability of CNT-based immunogens to trigger 520 
equivalent IgG responses with and without FA, thus further proving the self-adjuvanting properties 
of CNTs. 
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Fig. 4. Titer and affinity of the anti-azoxystrobin IgG response in mice for the four CNT–BSA–AZc6 
immunogens after the fourth dose with 2 µg of protein conjugate 5 with FA (dark grey bars) and without FA 525 
(pale grey bars). The bars are the mean values from three mice immunized with the same construct and the 
triangles are the individual values for each mouse response.  
 
4. Conclusions 
We have employed microwave-assisted procedures to achieve fast and easy covalent 530 
functionalization of SWNTs and MWNTs, introducing carboxylate moieties that were subsequently 
reacted with ethylendiamine to incorporate amine residues. The reactions of these aminated CNTs 
with protein-hapten conjugate 5 gave the corresponding immunogenic derivatives. The initial 
application of the radical insertion or oxidative fragmentation methods for both types of pristine 
CNTs resulted in four types of CNT immunogens, differing in shape and size. The ELISA and 535 
immuno-TEM techniques allowed detailed characterization of the prepared immunogens, ensuring 
that the hapten was properly exposed to the surrounding medium and therefore to the immune 
system. The obtained antisera displayed excellent titers and affinities to the model hapten, thus 
showing the capability of CNTs to act as vehicles for enhancing the immune response, even with 
low amounts of a protein conjugate. This result opens the door to the biotechnological possibility of 540 
producing valuable antibodies for other haptens or even whole proteins, particularly if they are 
difficult to obtain and purify in the quantities required for conventional immunization protocols. 
Moreover, CNT-based immunogens were able to work very efficiently even without conventional 
water-in-oil adjuvants, acting as “bacteria-like” antigens with a self-adjuvanting capacity. This 
finding, beyond its relevance for basic science and its interest as proof–of–concept, could have 545 
important practical implications in antibody production because immunization procedures not 
involving mineral oil adjuvants are faster, cheaper and less painful to animals. Finally, CNT-based 
immunogens behaved differently depending on the size and shape of their particles. The shorter 
immunogens (1c and 2c) produced better responses than the longer ones (3c and 4c), most likely 
because CNTs less than 1 µm long are better phagocytosed and engulfed by APCs, although other 550 
characteristics associated with the nanoparticle size, such as hydrophobicity and surface antigen 
density, cannot be discarded. Overall, short and thick CNTs constructs (2c) performed optimally as 
delivery vehicles, producing suitable IgG responses even when loaded with just 0.05 µg of the 
protein conjugate. 
  555 
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